List of Excipients in Branded Drug VESICARE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Astellas Pharma US Inc	VESICARE	solifenacin succinate	51248-250	ACESULFAME POTASSIUM
Astellas Pharma US Inc	VESICARE	solifenacin succinate	51248-250	CARBOMER HOMOPOLYMER TYPE
Astellas Pharma US Inc	VESICARE	solifenacin succinate	51248-250	DIMETHICONE

VESICARE Excipient Strategy and Commercial Opportunities for Solifenacin

Last updated: August 16, 2026

Vesicare contains solifenacin succinate, an oral muscarinic M3-receptor antagonist used for overactive bladder. Its commercial opportunity has shifted from molecule-level exclusivity to differentiated dosage forms, pediatric delivery, adherence, palatability, manufacturing efficiency, and formulation intellectual property. The conventional tablet is a mature generic market. Vesicare LS oral suspension and patient-friendly solifenacin delivery systems offer the strongest remaining formulation opportunities.

What excipients are used in Vesicare tablets?

Vesicare tablets use a conventional immediate-release excipient system designed for chemical stability, tablet strength, disintegration, coating, and acceptable appearance.

Component	Functional role
Lactose monohydrate	Diluent and tablet-volume builder
Corn starch	Binder and disintegrant
Hypromellose	Film-forming coating polymer
Magnesium stearate	Lubricant
Talc	Glidant and coating aid
Titanium dioxide	Opacifier and pigment
Ferric oxide pigments	Tablet-color identification

The FDA label identifies Vesicare tablets as 5 mg and 10 mg solifenacin succinate products. The products are film-coated, immediate-release tablets supplied by Astellas Pharma US at the time of the reference labeling (U.S. Food and Drug Administration [FDA], 2023a).

The tablet formulation is technically conventional. It does not require a modified-release matrix, lipid system, enteric coating, amorphous solid dispersion, or specialized permeability enhancer. That limits the defensibility of a copycat product based only on excipient substitution.

Which excipient strategies are commercially attractive for solifenacin?

The most attractive strategies target patient populations and administration barriers rather than basic tablet manufacture.

Lactose-free and low-allergen formulations

Lactose is used in the conventional Vesicare tablet. A lactose-free tablet could target patients with lactose intolerance, excipient sensitivity, or preference for simplified labeling.

Potential replacement systems include:

• Mannitol for a low-moisture, water-soluble diluent
• Microcrystalline cellulose for compactibility
• Dibasic calcium phosphate for high-density tablets
• Pregelatinized starch for binding and disintegration
• Crospovidone or croscarmellose sodium for rapid disintegration

The commercial value is moderate. Lactose-free positioning can support hospital formularies, specialty pharmacies, and private-label products, but it is unlikely to create substantial pricing power in a mature generic market without a meaningful clinical or handling advantage.

Direct-compression tablets

A direct-compression formulation could reduce wet-granulation steps, drying requirements, processing time, and manufacturing cost. A candidate system would combine a directly compressible filler, superdisintegrant, glidant, and lubricant.

A typical development approach would evaluate:

• Microcrystalline cellulose or spray-dried mannitol as the principal filler
• Crospovidone or sodium starch glycolate as the disintegrant
• Colloidal silicon dioxide as the glidant
• Magnesium stearate at the lowest concentration consistent with ejection performance

The primary risks are content uniformity at the low 5 mg dose, over-lubrication, dissolution variability, and segregation of the active pharmaceutical ingredient. Solifenacin succinate is potent, so uniform distribution is more important than tablet mass.

Orally disintegrating tablets

An orally disintegrating tablet could address patients with dysphagia, elderly patients, and patients who have difficulty taking tablets with water. The main formulation requirements are rapid disintegration, acceptable mouthfeel, mechanical strength, and low moisture uptake.

Possible excipient platforms include:

• Mannitol for cooling sensation and taste masking
• Crospovidone for rapid water uptake
• Low-substituted hydroxypropyl cellulose for tablet breakup
• Sucralose or acesulfame potassium for bitterness control
• Flavors compatible with the active and packaging system
• Polyvinylpyrrolidone or methacrylate-based taste-masking coatings

Solifenacin has a bitter taste risk typical of many amine-containing drug substances. Taste masking may require polymer coating, ion-exchange resin complexation, cyclodextrin complexation, or a multiparticulate approach. A conventional sweetener-only strategy is unlikely to be sufficient for a high-value pediatric product.

What excipients are relevant to Vesicare LS oral suspension?

Vesicare LS is a 1 mg/mL solifenacin succinate oral suspension approved for pediatric patients aged 2 years and older with neurogenic detrusor overactivity. It is administered with an oral syringe and requires shaking before use (FDA, 2023b).

The formulation’s commercial and technical value is higher than the standard tablet because it must control several variables simultaneously:

• Uniform drug distribution during storage and dosing
• Sedimentation rate
• Resuspendability
• Viscosity
• Palatability
• Microbial preservation
• Dose accuracy through an oral syringe
• Chemical stability in an aqueous environment

The label identifies a suspension-based formulation with pharmaceutical excipients that support wetting, viscosity control, preservation, and physical stability. The product is packaged with a dosing device, making the delivery system part of the commercial product rather than a secondary accessory.

Suspension excipient platforms

A generic or improved solifenacin suspension could evaluate:

• Microcrystalline cellulose and carboxymethylcellulose as structured-vehicle suspending agents
• Xanthan gum for low-concentration viscosity control
• Carbomer for suspension stability at acidic pH
• Polysorbate or poloxamer surfactants for wetting
• Glycerin or propylene glycol for mouthfeel and cosolvency
• Sodium citrate or phosphate buffers for pH control
• Methylparaben, propylparaben, potassium sorbate, or alternative preservative systems
• Sucrose, sorbitol, sucralose, or acesulfame potassium for sweetness

The formulation must balance viscosity against syringeability. A vehicle that prevents sedimentation but requires excessive force through the oral syringe can reduce dose accuracy and caregiver acceptance.

Preservative-free suspension opportunities

A preservative-free formulation could have commercial value for children with preservative sensitivity and for institutions seeking simplified excipient profiles. The trade-off is a greater dependence on container-closure integrity, aseptic manufacture, single-dose packaging, refrigerated stability, or a validated in-use period.

Unit-dose sachets, ampoules, or prefilled oral syringes could support a preservative-free strategy. These presentations would increase packaging cost but could improve dose accuracy and reduce caregiver handling.

How strong is the Vesicare formulation patent estate?

The original solifenacin composition and use patents are mature, and generic solifenacin tablets are established in the U.S. market. The key remaining intellectual-property question concerns the pediatric suspension, delivery system, and any later formulation claims rather than the active ingredient itself.

IP category	Commercial status
Solifenacin active ingredient	Mature; generic competition exists
Conventional immediate-release tablet	Low differentiation; substitution is technically straightforward
Pediatric oral suspension	Higher formulation and regulatory value
Taste-masked liquid or ODT	Potentially protectable if claims cover a specific composition or performance
Dosing device and packaging	Potential device or combination-product protection
Method of use	May remain relevant where claims cover pediatric neurogenic detrusor overactivity
Manufacturing process	Potential barrier if it delivers superior content uniformity or stability

A complete patent opinion requires a current review of the FDA Orange Book, USPTO records, Patent Trial and Appeal Board proceedings, and relevant court dockets. The Orange Book remains the primary source for listed patents and regulatory exclusivity associated with approved drug products (FDA, 2024). The conventional Vesicare tablet should be treated as a genericized product, while Vesicare LS requires separate patent and regulatory analysis.

What is the Orange Book status of Vesicare?

Vesicare tablets have generic competition in the United States. FDA-approved generic solifenacin products include 5 mg and 10 mg tablet strengths from multiple manufacturers. The tablet market therefore has limited opportunity for a new entrant unless it offers lower cost, supply reliability, a differentiated excipient profile, or a new dosage form.

Vesicare LS should be analyzed separately from the tablet because an oral suspension may have different listed patents, exclusivity periods, and abbreviated new drug application pathways. A company seeking to enter the suspension market would need to assess:

1. Whether the reference product has current Orange Book-listed patents.
2. Whether the proposed product can use an ANDA or requires a 505(b)(2) application.
3. Whether the applicant must submit Paragraph IV certifications.
4. Whether pediatric exclusivity or other regulatory exclusivity affects approval timing.
5. Whether the proposed product is pharmaceutically equivalent and therapeutically equivalent to the listed reference product.

A suspension with a materially different formulation, indication, concentration, dosing device, or administration method may be more suitable for a 505(b)(2) pathway than a conventional ANDA, depending on the reference product and the proposed labeling (FDA, 2023c).

When does solifenacin lose exclusivity?

Solifenacin tablet exclusivity has already expired in practical commercial terms because FDA-approved generic tablets are available. The relevant business question is no longer loss of molecule exclusivity. It is whether a new suspension or delivery platform can obtain separate protection.

Potential protection periods can arise from:

• New formulation patents
• New method-of-use patents
• Pediatric exclusivity
• New dosage-form exclusivity
• Orphan-drug exclusivity, if the product qualifies for a separate orphan indication
• Patent term adjustment or restoration for later-issued patents

Pediatric exclusivity generally adds six months to qualifying listed patents or regulatory exclusivity, but it does not create a new, independent patent term for every product claim (FDA, 2023c).

Which companies are competing in solifenacin?

Competition exists at three levels.

Originator and branded products

Astellas developed Vesicare and commercialized the branded tablet and pediatric oral suspension. The brand retains value through physician familiarity, formulation continuity, and pediatric positioning.

Generic tablet manufacturers

Generic competition includes large multinational and specialty generic companies that manufacture or market solifenacin succinate tablets. The market is typically price-sensitive, with supply reliability and channel access more important than excipient differentiation.

Formulation and specialty pharmaceutical companies

The higher-value opportunity lies with companies developing:

• Pediatric liquids
• Orally disintegrating tablets
• Sprinkle formulations
• Taste-masked multiparticulates
• Unit-dose preservative-free suspensions
• Combination products with oral dosing devices
• Lower-cost products for public-sector procurement

Companies with pediatric formulation, oral-liquid manufacturing, and device-combination capabilities are better positioned than tablet-only generic manufacturers.

What generic entry risks exist for Vesicare LS?

A generic or follow-on suspension faces greater execution risk than a tablet.

Bioequivalence and product-performance risk

For an oral suspension, the applicant must control particle size, viscosity, sedimentation, redispersion, assay uniformity, dissolution or release behavior, and dose delivery. Differences in suspending agents can affect the in vivo performance of the product.

Microbiological risk

Aqueous products require validated preservative effectiveness, microbial limits, and container-closure controls. The formulation must remain stable throughout the labeled in-use period.

Device risk

The oral syringe must deliver the labeled dose across the full range of expected use. Syringe compatibility, graduations, extractables, and caregiver handling can affect regulatory acceptance and product liability exposure.

Pediatric acceptability risk

Taste, viscosity, aftertaste, dosing volume, and storage requirements directly affect adherence. A product that matches the reference product analytically but performs poorly in caregiver use may lose commercial share.

What commercial opportunities exist beyond Vesicare tablets?

The strongest opportunities are in differentiated delivery and lifecycle management.

Opportunity	Value proposition	Commercial attractiveness
Low-cost generic tablet	Price and supply competition	Low to moderate
Lactose-free tablet	Simplified excipient profile	Moderate
Orally disintegrating tablet	Dysphagia and convenience	Moderate
Pediatric oral suspension	Pediatric neurogenic bladder	High
Preservative-free liquid	Sensitive populations and institutional use	Moderate to high
Taste-masked multiparticulate	Pediatric adherence and flexible dosing	High
Unit-dose oral syringe	Dose accuracy and convenience	Moderate to high
Combination product with adherence support	Caregiver usability	Moderate
Novel long-acting delivery	Reduced dosing frequency	High technical risk

An improved pediatric product could compete on lower dosing volume, better taste, no refrigeration, longer in-use stability, preservative reduction, or a more accurate dosing device. Those claims are more commercially meaningful than replacing one standard tablet filler with another.

How should a company prioritize excipient development?

A practical development sequence is:

1. Select the target population and dosage form.
2. Define the regulatory pathway before locking the formulation.
3. Screen excipients for compatibility with solifenacin succinate.
4. Establish taste, viscosity, redispersibility, and dose-uniformity targets.
5. Build a design space around pH, preservative concentration, particle size, and rheology.
6. Test the complete product, including bottle, closure, syringe, and labeling.
7. Map formulation features against published and pending patent claims.
8. Quantify manufacturing cost and expected price erosion before investing in a differentiated presentation.

For a tablet, the priority should be manufacturing efficiency and supply reliability. For an oral suspension, the priority should be pediatric acceptability, physical stability, microbiological control, and device performance.

Key Takeaways

• Vesicare tablets use a conventional excipient system and face established generic competition.
• Lactose-free and direct-compression tablets may reduce cost or broaden patient acceptance but offer limited defensibility.
• Vesicare LS oral suspension is the stronger commercial opportunity because pediatric delivery creates higher technical and regulatory barriers.
• Suspension development must control sedimentation, redispersion, viscosity, preservative effectiveness, taste, and syringe dosing accuracy.
• The most credible formulation IP opportunities involve specific suspension systems, taste masking, preservative-free packaging, dosage devices, and pediatric methods of use.
• Generic tablet entry risk is low relative to oral-suspension entry risk.
• A current Orange Book and patent-docket review is essential before relying on any Vesicare LS launch date or Paragraph IV strategy.

FAQs

Is Vesicare lactose-free?

No. The conventional Vesicare tablet formulation includes lactose monohydrate according to FDA labeling. A lactose-free generic could use mannitol, microcrystalline cellulose, or another suitable diluent.

Can solifenacin be formulated as an orally disintegrating tablet?

Yes. An orally disintegrating solifenacin product is technically feasible, but taste masking, low-dose content uniformity, mechanical strength, and moisture protection are central development issues.

What is the best preservative for a solifenacin oral suspension?

No single preservative is universally optimal. The choice depends on pH, container closure, microbial challenge results, excipient compatibility, and the intended in-use period. Methylparaben, potassium sorbate, and benzoate systems are possible candidates subject to formulation testing.

Would a solifenacin suspension require an ANDA or a 505(b)(2) application?

The pathway depends on the proposed product’s pharmaceutical equivalence, formulation, concentration, dosage device, labeling, and relationship to the reference product. A materially different liquid presentation may create a 505(b)(2) rationale, while a sufficiently equivalent product may qualify for an ANDA.

Is the solifenacin tablet market attractive for a new generic manufacturer?

Only selectively. The tablet market is mature and price-sensitive. The better opportunities are contract manufacturing, supply-reliable products, private-label distribution, excipient-differentiated tablets, and pediatric or adherence-focused dosage forms.

References

1. U.S. Food and Drug Administration. (2023a). Vesicare (solifenacin succinate) tablets: Prescribing information.
2. U.S. Food and Drug Administration. (2023b). Vesicare LS (solifenacin succinate) oral suspension: Prescribing information.
3. U.S. Food and Drug Administration. (2023c). Applications covered by section 505(b)(2).
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2024). Inactive ingredient database.